Additionally, since we reported that intravenously administered EVs could increase the risk of fatal pulmonary embolism in mice,31 exploring alternative delivery methods for CD38‐EVs beyond i.v routes is essential. The gene discussed is CD38; the disease is pulmonary embolism.